Continuing Imatinib Treatment for Chronic Myeloid Leukemia Patients Who Had Serious Adverse Events at the Onset of Therapy

Publisher： Karger

E-ISSN： 1421-9662|137|3|158-162

ISSN： 0001-5792

Source： Acta Haematologica, Vol.137, Iss.3, 2017-04, pp. : 158-162

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Long‐term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 57, Iss. 3, 2018-03 ,pp. : 332-338

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in Expression of Apoptosis-Related Genes Are Linked to the Molecular Response to Imatinib Treatment in Chronic-Phase Chronic Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 83-90

Karger

Access to resources Recommend Favorite

Imatinib plus Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients Who Have Achieved Partial or Complete Cytogenetic Response while on Imatinib

By  

Case Reports in Oncology, Vol. 4, Iss. 1, 2011-04 ,pp. : 192-197

Karger

Access to resources Recommend Favorite

Apoptosis-Related Gene Expression Profile in Chronic Myeloid Leukemia Patients after Imatinib Mesylate and Dasatinib Therapy

By  

Acta Haematologica, Vol. 133, Iss. 4, 2015-02 ,pp. : 354-364

Karger

Access to resources Recommend Favorite

Nilotinib Can Override Dasatinib Resistance in Chronic Myeloid Leukemia Patients with Secondary Resistance to Imatinib First-Line Therapy

By  

Acta Haematologica, Vol. 118, Iss. 3, 2007-09 ,pp. : 162-164

Karger

Access to resources Recommend Favorite